2024年度欣博盛自產(chǎn)試劑盒獎(jiǎng)學(xué)金計(jì)劃

使用欣博盛品牌（NeoBioscience）ELISA試劑盒在 SCI 期刊上發(fā)表學(xué)術(shù)文章，

文章中注明試劑盒購(gòu)自“ NeoBioscience Technology Co. Ltd. "，

滿(mǎn)足條件，即可申請(qǐng)獎(jiǎng)勵(lì)！

現(xiàn)獎(jiǎng)學(xué)金申請(qǐng)可優(yōu)先讓客戶(hù)通過(guò)填報(bào)，

但仍可直接通過(guò)原本的郵件/業(yè)務(wù)員/經(jīng)銷(xiāo)商等方式聯(lián)系。

使用欣博盛品牌(Neobioscience) ELISA試劑盒在SCI期刊上發(fā)表學(xué)術(shù)文章并注明試劑盒購(gòu)自“Neobioscience Technology Co,Ltd."

申請(qǐng)：登錄欣博盛生物    在"獎(jiǎng)學(xué)金申請(qǐng)"頁(yè)面在線(xiàn)提交申請(qǐng)表。

收到您的獎(jiǎng)學(xué)金申請(qǐng)后，欣博盛生物將在7個(gè)工作日內(nèi)審核并處理。審核通過(guò)后，將根據(jù)您文章的影響因子(IF)發(fā)放獎(jiǎng)勵(lì)。

IF越高，獎(jiǎng)勵(lì)越多！欣博盛生物祝您多發(fā)Paper多拿獎(jiǎng)勵(lì)！

● 申請(qǐng)文章需于2024年發(fā)表（以見(jiàn)刊時(shí)間為準(zhǔn)），文章影響因子（IF）以申請(qǐng)時(shí)該期刊的數(shù)據(jù)為準(zhǔn)；

● 獲獎(jiǎng)老師為文章第一作者或共同第一作者，每篇文章僅能申請(qǐng)一次獎(jiǎng)勵(lì)；

● 文章內(nèi)使用指標(biāo)與購(gòu)買(mǎi)的試劑盒指標(biāo)須一致；

● 以96T試劑盒為單位計(jì)算，申請(qǐng)文章總數(shù)不能多于三年內(nèi)購(gòu)買(mǎi)試劑盒的總數(shù)；

● 購(gòu)物金僅限購(gòu)買(mǎi)欣博盛ELISA時(shí)從單筆訂單中抵扣；

● 本活動(dòng)最終解釋權(quán)歸欣博盛生物所有。

期刊：Translational Oncology, 2023

首都醫(yī)科大學(xué)宣武醫(yī)院-張老師

使用產(chǎn)品：Human IFN-γ and TNF-α ELISA Kit

● 我用過(guò)貴公司的多種細(xì)胞因子的ELISA檢測(cè)試劑盒，包括顆粒酶B和穿孔素等。首先覺(jué)得試劑盒的質(zhì)量就很好，每次檢測(cè)后標(biāo)準(zhǔn)曲線(xiàn)均一性不錯(cuò)，數(shù)據(jù)的可重復(fù)性強(qiáng)。其次試劑盒使用方便，簡(jiǎn)單，說(shuō)明書(shū)寫(xiě)得很明確，操作起來(lái)可重復(fù)性也很好。總之，使用貴公司的ELISA試劑盒體驗(yàn)極-佳，接下來(lái)的科研工作如果做到ELISA實(shí)驗(yàn)，也會(huì)首-選欣博盛的產(chǎn)品。

期刊：Annals of the New York Academy of Sciences, 2023

武漢大學(xué)口腔醫(yī)院-彭老師

使用產(chǎn)品：Mouse IL-1β ELISA Kit

● 非常方便，并且說(shuō)明書(shū)上的步驟也非常詳細(xì)，上手很快，反應(yīng)也比較靈敏，副孔之間以及每次重復(fù)的結(jié)果相差都不大，擬合出來(lái)的標(biāo)準(zhǔn)曲線(xiàn)R2值比較高，可信度也很不錯(cuò)。

期刊：Immunity, 2023

南方醫(yī)科大學(xué)-曾老師

使用產(chǎn)品：Mouse TNF-α, IL-1β, IL-6 and IL-18 ELISA Kits

● 我用過(guò)好多欣博盛ELISA試劑盒，包括鼠的IL-1β、TNF-α等，總體感覺(jué)不錯(cuò)。比起進(jìn)口試劑盒，價(jià)格要公道便宜的多；與國(guó)內(nèi)其他公司相比，應(yīng)該算是國(guó)產(chǎn)頂級(jí)梯隊(duì)的產(chǎn)品了，值得信賴(lài)。

● LV J W Y, YIN J H, et al. 2023. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nature Medicine [J], 6 June 2023. (IF=82.9)

● SHI X, SUN Q, HOU Y, et al. 2023. Recognition and maturation of IL-18 by caspase-4 noncanonical inflammasome. Nature [J], 22 November 2023. (IF=64.8)

● CHEN X W R, LI L, et al. 2023. Pregnancy-induced changes to the gut microbiota drive macrophage pyroptosis and exacerbate septic inflammation. Immunity [J], 14 February 2023. (IF=32.4)

● CHENG J Y J, LIU Y, et al. 2023. Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment. Cell Metabolism [J], 12 May 2023. (IF=29)

● ZENG Y W R, WANG F, et al. 2023. Liberation of daidzein by gut microbial β-galactosidase suppresses acetaminophen-induced hepatotoxicity in mice. Cell Host & Microbe [J], 25 April 2023. (IF=30.3)

● LIANG W Y Y, GONG S, et al. 2023. Airway dysbiosis accelerates lung function decline in chronic obstructive pulmonary disease. Cell Host & Microbe [J], 15 May 2023. (IF=30.3)

● LIU W Z S, LI Q, et al. 2023. Lactate modulates iron metabolism by binding soluble adenylyl cyclase. Cell Metabolism [J], 21 July 2023. (IF=29)

● WANG J Z L, WU N, et al. 2023. Inhibition of Phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells. Drug Resistance Updates [J], 14 June 2023. (IF=24.3)

● GUO Y Z X N, SU S, et al. 2023. β-adrenoreceptor-triggered PKA activation negatively regulates the innate antiviral response. Cellular & Molecular Immunology [J], 5 January 2023. (IF=24.1)

● SHI Y S J, SUN Y, et al. 2023. A Hierarchical 3D Graft Printed with Nanoink for Functional Craniofacial Bone Restoration. Advanced Functional Materials [J], 6 June 2023. (IF=19)

● LI X L Z, WANG P, et al. 2023. Dopamine‐Integrated Nanointerface between Fibrillar Matrix and Hydrophilic Nanohydroxyapatite Regulates Immune Microenvironment to Boost Endogenous Bone Regeneration. Advanced Functional Materials [J], 17January 2023. (IF=19)

● ZHANG X Y Y, LI J, et al. 2023. Engineered Oxygen Factories Synergize with STING Agonist to Remodel Tumor Microenvironment for Cancer Immunotherapy. Advanced Functional Materials [J], 19 June 2023. (IF=19)

● ZHANG L H S, MOVAHEDI F, ET AL. 2023. Amyloid-β/Tau burden and neuroinflammation dual-targeted nanomedicines synergistically restore memory and recognition of Alzheimer’s disease mice. Nano Today [J], 20 February 2023. (IF=17.4)

● SHI X, SUN Q, HOU Y, et al. 2023. Recognition and maturation of IL-18 by caspase-4 noncanonical inflammasome. Nature [J], 624: 442-450.

● ZHOU P, SHE Y, DONG N, et al. 2018. Alpha-kinase 1 is a cytosolic innate immune receptor for bacterial ADP-heptose. Nature [J], 561: 122-126.

● SHI J, ZHAO Y, WANG K, et al. 2015. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature [J], 526: 660-665.

● XU H, YANG J, GAO W, et al. 2014. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature [J], 513: 237-241.

● ZHAO Y, YANG J, SHI J, et al. 2011. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature [J], 477: 596-600.

欣博盛生物科技有限公司